MX2009013082A - Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. - Google Patents
Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.Info
- Publication number
- MX2009013082A MX2009013082A MX2009013082A MX2009013082A MX2009013082A MX 2009013082 A MX2009013082 A MX 2009013082A MX 2009013082 A MX2009013082 A MX 2009013082A MX 2009013082 A MX2009013082 A MX 2009013082A MX 2009013082 A MX2009013082 A MX 2009013082A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- complement
- prevention
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
Abstract
La presente invención se refiere a anticuerpos contra C3b y a la prevención y tratamiento del trastorno asociado con el complemento utilizando tales anticuerpos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93372107P | 2007-06-07 | 2007-06-07 | |
US5506808P | 2008-05-21 | 2008-05-21 | |
PCT/US2008/065771 WO2008154251A2 (en) | 2007-06-07 | 2008-06-04 | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013082A true MX2009013082A (es) | 2010-01-15 |
Family
ID=39712089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013082A MX2009013082A (es) | 2007-06-07 | 2008-06-04 | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. |
Country Status (18)
Country | Link |
---|---|
US (2) | US8012473B2 (es) |
EP (1) | EP2162470A2 (es) |
JP (3) | JP5683265B2 (es) |
KR (3) | KR101572700B1 (es) |
CN (1) | CN101809034B (es) |
AR (1) | AR066916A1 (es) |
AU (1) | AU2008262048B2 (es) |
BR (1) | BRPI0812767A2 (es) |
CA (1) | CA2690124A1 (es) |
CL (1) | CL2008001656A1 (es) |
IL (1) | IL201820A0 (es) |
MX (1) | MX2009013082A (es) |
PE (1) | PE20090416A1 (es) |
RU (1) | RU2473563C2 (es) |
SG (2) | SG182165A1 (es) |
TW (2) | TWI557137B (es) |
WO (1) | WO2008154251A2 (es) |
ZA (1) | ZA200907575B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
PE20091388A1 (es) * | 2007-11-02 | 2009-09-24 | Novartis Ag | Moleculas y metodos para modular el componente de complemento |
US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
EP2453906A4 (en) | 2009-07-02 | 2014-01-15 | Musc Found For Res Dev | METHOD FOR STIMULATING THE LIVER REGENERATION |
NZ600393A (en) | 2009-11-05 | 2014-08-29 | Alexion Cambridge Corp | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
WO2011084496A1 (en) * | 2009-12-16 | 2011-07-14 | Abbott Biotherapeutics Corp. | Anti-her2 antibodies and their uses |
US20130084584A1 (en) * | 2010-03-31 | 2013-04-04 | Anna Blom | Method to detect tissue degradation leading to inflammation |
CA2799192A1 (en) | 2010-05-14 | 2011-11-17 | The Regents Of The University Of Colorado, A Body Corporate | Improved complement receptor 2 (cr2) targeting groups |
CN103249432A (zh) | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
US8940490B2 (en) | 2010-11-29 | 2015-01-27 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
WO2013152024A1 (en) * | 2012-04-03 | 2013-10-10 | Novelmed Therapeutics, Inc | Humanized and chimeric anti-factor c3 antibodies and uses thereof |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
AU2014209350B8 (en) * | 2013-01-23 | 2019-04-18 | Department Of Veterans Affairs (Us) | Targeting constructs based on natural antibodies and uses thereof |
EP3011345B1 (en) | 2013-08-07 | 2017-10-04 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (ahus) biomarker proteins |
WO2015099838A2 (en) | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
KR20230149865A (ko) * | 2014-02-26 | 2023-10-27 | 알러간, 인코포레이티드 | 보체 성분 c5 항체 |
JP6643244B2 (ja) | 2014-02-27 | 2020-02-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | 補体因子Bb抗体 |
EP3973994A1 (en) | 2014-06-12 | 2022-03-30 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
AU2015304079B2 (en) * | 2014-08-20 | 2021-05-13 | Stichting Sanquin Bloedvoorziening | Factor H potentiating antibodies and uses thereof |
ES2900998T3 (es) | 2015-01-28 | 2022-03-21 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento |
RU2584582C1 (ru) * | 2015-03-16 | 2016-05-20 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело сс3-4 к конформационному эпитопу с3 человека, штамм гибридной днк мыши рккк(п)764д - продуцент моноклонального антитела сс3-4 |
CN108697759B (zh) | 2015-12-16 | 2022-08-02 | Ra制药公司 | 补体活性的调节剂 |
GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
BR112019011053A2 (pt) | 2016-12-07 | 2019-10-15 | Ra Pharmaceuticals Inc | moduladores da atividade do complemento |
SG10202111663PA (en) * | 2017-02-27 | 2021-12-30 | Regeneron Pharma | Humanized model of kidney and liver disorders |
TW201938184A (zh) | 2017-12-04 | 2019-10-01 | 美商Ra製藥公司 | 補體活性之調節劑 |
GB201800620D0 (en) * | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
TWI833742B (zh) | 2018-04-03 | 2024-03-01 | 美商恩格姆生物製藥公司 | C3結合劑及其使用方法 |
RU2687609C1 (ru) * | 2018-05-30 | 2019-05-15 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека |
WO2019238674A1 (en) * | 2018-06-11 | 2019-12-19 | Aarhus Universitet | Single domain antibodies for complement regulation |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
JP2022527508A (ja) | 2019-03-29 | 2022-06-02 | ラ ファーマシューティカルズ インコーポレイテッド | 補体モジュレータ及び関連方法 |
BR112021017820A2 (pt) | 2019-04-24 | 2022-02-08 | Ra Pharmaceuticals Inc | Composições e métodos para modulação da atividade de complemento |
WO2021011903A1 (en) | 2019-07-17 | 2021-01-21 | Gemini Therapeutics Inc. | Factor h potentiating antibodies and uses thereof |
WO2023212298A1 (en) * | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Bispecific antibodies and methods of treating ocular disease |
WO2024064732A2 (en) * | 2022-09-20 | 2024-03-28 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
TW458985B (en) * | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
PL328706A1 (en) * | 1996-03-07 | 1999-02-15 | Imutran Ltd | Downward control of resistant convertase c3 |
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
EP3260467A1 (en) * | 1998-02-20 | 2017-12-27 | Genentech, Inc. | Inhibitors of complement activation |
WO2003102157A2 (en) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Synthetic antibody phage libraries |
US7959919B2 (en) * | 2003-11-19 | 2011-06-14 | Novelmed Therapeutics, Inc. | Method of inhibiting factor B-mediated complement activation |
US20090004183A1 (en) * | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
-
2008
- 2008-06-04 WO PCT/US2008/065771 patent/WO2008154251A2/en active Application Filing
- 2008-06-04 SG SG2012041125A patent/SG182165A1/en unknown
- 2008-06-04 CA CA2690124A patent/CA2690124A1/en not_active Abandoned
- 2008-06-04 EP EP08756688A patent/EP2162470A2/en not_active Withdrawn
- 2008-06-04 KR KR1020107000198A patent/KR101572700B1/ko not_active IP Right Cessation
- 2008-06-04 CN CN200880102282.9A patent/CN101809034B/zh not_active Expired - Fee Related
- 2008-06-04 KR KR1020157002416A patent/KR20150029002A/ko active IP Right Grant
- 2008-06-04 SG SG10201608952QA patent/SG10201608952QA/en unknown
- 2008-06-04 AU AU2008262048A patent/AU2008262048B2/en not_active Ceased
- 2008-06-04 RU RU2009149385/10A patent/RU2473563C2/ru not_active IP Right Cessation
- 2008-06-04 BR BRPI0812767-0A2A patent/BRPI0812767A2/pt not_active IP Right Cessation
- 2008-06-04 JP JP2010511295A patent/JP5683265B2/ja not_active Expired - Fee Related
- 2008-06-04 MX MX2009013082A patent/MX2009013082A/es active IP Right Grant
- 2008-06-04 KR KR1020177004887A patent/KR20170023212A/ko not_active Application Discontinuation
- 2008-06-06 US US12/157,073 patent/US8012473B2/en not_active Expired - Fee Related
- 2008-06-06 CL CL2008001656A patent/CL2008001656A1/es unknown
- 2008-06-06 PE PE2008000973A patent/PE20090416A1/es not_active Application Discontinuation
- 2008-06-06 TW TW103111348A patent/TWI557137B/zh not_active IP Right Cessation
- 2008-06-06 TW TW097121292A patent/TWI441832B/zh not_active IP Right Cessation
- 2008-06-06 AR ARP080102436A patent/AR066916A1/es unknown
-
2009
- 2009-10-28 ZA ZA2009/07575A patent/ZA200907575B/en unknown
- 2009-10-29 IL IL201820A patent/IL201820A0/en not_active IP Right Cessation
-
2011
- 2011-07-18 US US13/135,907 patent/US8377437B2/en not_active Expired - Fee Related
-
2014
- 2014-02-05 JP JP2014020001A patent/JP5980249B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-26 JP JP2016145975A patent/JP2016204382A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013082A (es) | Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
PH12013502230A1 (en) | Multispecific antibodies | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
IN2012DN03883A (es) | ||
MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
MY172372A (en) | Compositions and methods for lowering triglycerides | |
WO2012034116A3 (en) | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
MY165728A (en) | Selective glycosidase inhibitors and uses thereof | |
MX2009006627A (es) | Quinazolinas para la inhibicion de pdk1. | |
JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX2011009539A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso. | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
MA34598B1 (fr) | Procédés et compositions pour traiter le cancer du poumon | |
MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
NZ607588A (en) | Antibodies against human TWEAK and uses thereof | |
EA200802072A1 (ru) | Ликопин для лечения нарушения обмена веществ | |
MX2009009693A (es) | Metodos para activar irs-1 y akt. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |